A new blood test for diagnosis of Alzheimer's disease
Diagnosis of Alzheimer's disease is mainly recognized by the onset of common clinical criteria related to Alzheimer's disease such as cognitive impairment. So there is no definite treatment for Alzheimer as the pathology is irreversible.
On the other side, medical studies showed that there are microtubules that form a structure responsible for transporting nutrients within brain cells. In the healthy brain, certain protein (called tau protein) helps these microtubules to remain straight and strong, but in patients of Alzheimer's disease tau protein collapses into abnormal structures called tangles.
When tau tangles are formed, microtubules undergo multiple damages and become unable to transport nutrients within brain cells, which eventually lead to death of brain cells and development of cognitive impairment related to Alzheimer's disease.
A new research from Lund University in Sweden showed that there is a promising hope in diagnosis and treatment of Alzheimer through a new blood test which is able to detect the disease as early as 20 years before the onset of cognitive impairment of Alzheimer.
This test depends on measuring phospho-tau217 (the test is called p-tau217), which is the primary active form of tau tangles. This blood test will be a promising step in diagnosis, early detection and study of Alzheimer.